These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35412226)

  • 1. Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer.
    Florou V; Garrido-Laguna I
    Curr Oncol Rep; 2022 Sep; 24(9):1107-1112. PubMed ID: 35412226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TIGIT therapies for solid tumors: a systematic review.
    Rousseau A; Parisi C; Barlesi F
    ESMO Open; 2023 Apr; 8(2):101184. PubMed ID: 36933320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
    Wu J; Ren D; Bi H; Yi B; Wang H
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
    Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
    Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT as an emerging immune checkpoint.
    Harjunpää H; Guillerey C
    Clin Exp Immunol; 2020 May; 200(2):108-119. PubMed ID: 31828774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.
    Jin S; Zhang Y; Zhou F; Chen X; Sheng J; Zhang J
    Front Oncol; 2022; 12():1091782. PubMed ID: 36605439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy.
    Mori M; Kanayama M; Kuwata T; Manabe T; Nemoto Y; Nishizawa N; Oyama R; Matsumiya H; Nabe Y; Taira A; Takenaka M; Yoneda K; Kuroda K; Tanaka F
    Sci Rep; 2023 Feb; 13(1):3270. PubMed ID: 36841853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
    Cai L; Li Y; Tan J; Xu L; Li Y
    J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
    Yeo J; Ko M; Lee DH; Park Y; Jin HS
    Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
    Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
    Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
    Xiao Y; Chen P; Luo C; Xu Z; Li X; Liu L; Zhao L
    Cancer Treat Res Commun; 2021; 29():100467. PubMed ID: 34598062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.
    Rotte A; Sahasranaman S; Budha N
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint targeting TIGIT in hepatocellular carcinoma.
    Zheng Q; Xu J; Gu X; Wu F; Deng J; Cai X; Wang G; Li G; Chen Z
    Am J Transl Res; 2020; 12(7):3212-3224. PubMed ID: 32774695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
    Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
    J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.